Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

stance and the improved patient comfort due to lower PONV supports CeNeS justification of a substantial price premium for M6G compared to morphine.

We are actively pursuing potential partners for M6G and are confident that agreements can be reached. We are well positioned to deliver significant value to shareholders by the successful commercialisation of M6G".

- END -

CeNeS Pharmaceuticals plc will be announcing its preliminary results for the year ended 31 December 2006 on Wednesday 28 March 2007. On the same day the Company will be hosting an R&D presentation at the offices of Financial Dynamics. The presentation will start at 9:30am and is expected to conclude at 11am.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

The active potent metabolite of morphine, morphine-6-glucuronide (M6G), may offer therapeutic advantages over morphine in having an equivalent analgesic effect, but with a reduced tendency to cause nausea, vomiting and respiratory depression. Phase II and III clinical trials have sho
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:11/28/2008)...28 German biotech company,Partec ...HIV monitoring and,AIDS patient follow-up diagnos...e year 2008, 2.5 million patient tests have been p...ordable "CyFlow" system, supporting already,more ... introduction of the,Partec innovation, the avera...
(Date:11/26/2008)...utomation and intelligent clinical applications ta... level , , CHICAGO, Ill., Nov. 26 /PRNewswi...ens.com/healthcare ) highlights the ACUSON S2000(...e world,s first multi-use, automated volume breast...y and Annual Meeting of the Radiological Society o...
(Date:11/25/2008)...against expanding statin use broadly in wake of AH...ov. 25 JUPITER, a clinical trial s...r risk of healthy patients with elevated CRP, shou..., according to a national poll directed at health ...n the online poll conducted by medical news site M...
(Date:11/25/2008)...l Trial to Assess Survival of Patients Receiving L...able Hepatocellular Carcinoma , , BELLEVUE,...ology, Inc. (LSO) today announced the completion o... Light Infusion Therapy(TM) (Litx(TM)) as a treatm...), also known as hepatoma or primary liver cancer....
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Veterans for Americas 28VFA 29 Wounded Warrior Outreach Program Responds to Fort Drum in Aftermath of Report 12408 1Veterans for Americas 28VFA 29 Wounded Warrior Outreach Program Responds to Fort Drum in Aftermath of Report 12408 2New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 3443 1New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 3443 2Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 1Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 2Major scientific push to tackle agricultural productivity and food security in developing world 2285 1Major scientific push to tackle agricultural productivity and food security in developing world 2285 2Major scientific push to tackle agricultural productivity and food security in developing world 2285 3
(Date:12/2/2008)...NDO, Fla., Dec. 2 MEDai, Inc., hea...olutions provider, has added a new module,to its ...The new stand-alone,module monitors a population,...s and alerts stakeholders when there has been a de... Navigator Guidelines(TM) provides,real-time deci...
(Date:12/2/2008)...inal Special Features MLS Stars and Promotes Healt.../ -- Juniper Content Corporation,s (OTC Bulletin ...astest-growing Spanish-language children,s network... special Juega Como un MLS Pro , the climax of th...ue Soccer, on Sunday, December 7th at 7 PM EST. ,...
(Date:12/2/2008)...cts to File NDA with FDA in Early to Mid-2009 , ... Rx, the developers of PharmFilm(R) technology and...g thin film pharmaceutical products, and Strativa ... of Par Pharmaceutical Companies, Inc. (NYSE: PR...all pivotal bioequivalence studies for a thin film...
(Date:12/2/2008)...IN, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- C...l" or "the Company") (Nasdaq: CSKI ), a leading,... over-the-counter drugs in,the People,s Republic ...(Stanley) Hao was appointed Chief Financial Office...y,s Board of Directors. He replaces Yu-kun Zhang,...
Breaking Medicine News(10 mins):Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3
...or most teenagers a run up the stairs is simply th...or others the resulting breathlessness// and pound...icting a future vulnerability to panic symptoms. ...f Arkansas psychologist, has found that adolescent...
... certain gonorrhea strain has titillated the curio...enzyme, called prolyliminopeptidase//, which helps...s strain of gonorrhea. The existing diagnostic eva...w strain, making detection of gonorrhea extremely ...
... new research shows that nonsurgical embolization ...ecurrence rate and much quicker recovery than surg...eins in the testicle and scrotum). This condition ...ility problems—and can greatly impact quality of l...
...ew Delhi: India witnesses nearly 1.8 million tuber...menace the government// has cleared Rs. 11.56 bill...(RNTCP)-Phase II. As per government estimates, n...infected with TB bacillus but only 10 percent brea...
Other Medicine News:Health News:Panic may Lead to Serious Mental Health Problems in Adolescents 2Health News:Nonsurgical Therapy Highly Effective for Pain and Infertility in Men 2Health News:Government Allot More Funds for Revised TB Program 2
Standard reading test. "Clearing weather..."
Directional `E' and `C' test.
...These Low Contrast Flip charts contain 5 pages of ...ach page. Optotype size is 9.5M. Contrast levels a... can be used at several different distances. These...a different set of symbols to guard against memor...
...The PowerLab/4SP is a high-performance data acquis... applications including human and animal physiolog..., biochemistry, and biomedical engineering. The un...fast speeds (up to 200 000 samples per second cont...
Medicine Products: